US EditionOzempic-like drug significantly reduces frequency of chronic migraines in pilot study
ITALY, JUL 2 – A 12-week trial showed liraglutide halved migraine days in 31 patients with obesity and chronic migraine unresponsive to other treatments, according to Italian researchers.
- Italian researchers led by neurologist Simone Braca published this month a pilot study showing that liraglutide reduced migraine frequency in obese chronic migraine patients.
- The small trial with 31 patients was motivated by the need for better treatments for high-frequency migraines unresponsive to current medications.
- Participants received daily liraglutide injections for 12 weeks, after which average migraine days dropped from 19.8 to 10.7, nearly halving the monthly migraine burden.
- One participant became completely free of migraines, while mild gastrointestinal side effects like nausea occurred but resolved, and researchers emphasized that the effect appeared independent of weight loss.
- This proof-of-concept study suggests GLP-1 receptor agonists could offer a new treatment option for some chronic migraine sufferers and calls for larger trials to confirm these findings.
13 Articles
13 Articles
Can drinking soda help migraines? Doctors reveal whether bubbly drinks cure headaches or not
NEWYou can now listen to Fox News articles! For the 39 million Americans who suffer from migraines, finding effective relief can be a constant struggle – leading many to test out old wives’ tales. Some claim that applying potato slices to the forehead helps kill the complex headaches, while others submerge their feet in hot water in a desperate search for relief. Another remedy? Sipping soda, particularly Coke, is said to cure migraines. But do…
Popular weight-loss drugs show promising new power against debilitating migraines
GLP-1 drugs show promise for migraine relief, reducing headache days from 20 to 11 per month in adults with obesity, with benefits appearing within two weeks regardless of weight loss.
Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine sufferers cannot find relief in available drugs. Others experience side effects that prevent the use of certain available migraine medications.
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 38% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
